GlassScriptPhysician profile
Alexander Javier Alvarez
NPI 1558672691
$3,401.53
in general payments reported to CMS, 2019-2025
25 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $450 · 2021: $185 · 2022: $332 · 2023: $408 · 2024: $343 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.65 |
| Education | $110.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $602.18 | 2019-2024 | Nucala |
| Regeneron Healthcare Solutions, INC. | $531.25 | 2019-2025 | Dupixent |
| Genzyme Corporation | $402.79 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $297.86 | 2019-2022 | |
| Pfizer INC. | $184.76 | 2019-2022 | |
| Alk-Abello, INC | $155.01 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Grifols USA, LLC | $140.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $129.74 | 2019 | |
| Galderma Laboratories, L.P. | $127.56 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $121.82 | 2023 | Ayvakit |
| Biocryst US Sales Co., LLC | $116.15 | 2024 | Orladeyo |
| Mylan Specialty L.P. | $89.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.09 | 2019-2020 | |
| Csl Behring | $65.20 | 2020-2024 | Haegarda |
| Shire North American Group INC | $58.58 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $53.08 | 2019-2022 | |
| Kaleo, INC. | $52.73 | 2019-2020 | |
| Amgen INC. | $52.65 | 2022-2025 | |
| Philips North America LLC | $29.65 | 2019-2020 | |
| Ethicon US, LLC | $27.86 | 2019 | |
| Abbvie INC. | $23.98 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.98 | 2020 | |
| Hologic Sales and Service, LLC | $13.50 | 2025 | Aptima |
| Octapharma USA, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.